Persistent Dirofilaria asiatica microfilaremia persisted for more than a year in a Sri Lankan child
A 2-year-old girl in Sri Lanka carried Dirofilaria asiatica microfilariae in her blood for more than a year, even after repeated treatment with diethylcarbamazine. The case is unusual not only because patent human infection is rare, but because the parasite remained detectable after two initial treatment courses and cleared only after a third regimen that added albendazole.
For filariasis programs, that is not a small diagnostic footnote. It is a reminder that zoonotic filarial worms can move through surveillance systems built mainly for human lymphatic filariasis, blur microscopy-based classification, and complicate elimination work in places where canine reservoirs remain active.
A child with persistent bloodborne filarial infection
The child lived in Kalutara District and had trisomy 21. In April 2024, routine night blood smear surveillance identified an unidentified filarial parasite. Methylene blue staining showed unsheathed microfilariae with a rounded anterior end, 1–2 cephalic nuclei, and a curved tail, features consistent with Dirofilaria species.
No clinical signs of lymphatic filariasis were present. Investigators obtained a whole-blood sample and started oral diethylcarbamazine at 3 mg/kg/day for 12 days. One month later, night blood smear still showed microfilaremia, so a second course of diethylcarbamazine was given.
The patient did not return after that second treatment, and contact with the family was lost for nearly a year. When follow-up testing finally resumed, microscopy was still positive for microfilariae. The morphology again fit Dirofilaria spp., but both the Brugia Test Plus and the STANDARD Q Filariasis Antigen test were negative.
Persistence over that interval matters clinically. A blood parasite that remains visible after treatment raises the possibility of treatment failure, reinfection, or a host-parasite interaction that allows continued development inside a human who should function as a dead-end host.
Molecular testing identified Dirofilaria asiatica
Eight days after the persistent smear result, the child received a third 12-day course of diethylcarbamazine, this time at 6 mg/kg/day, together with albendazole 400 mg. Four weeks later, in July 2025, thick blood smear was negative for microfilariae.
The decisive step came from molecular characterization of the original 2024 blood sample. At the University of Melbourne, investigators extracted DNA and applied two nanopore-based metabarcoding assays. One targeted the mitochondrial cytochrome c oxidase 1 cox-1 gene. The second targeted nuclear 18S ribosomal RNA, ITS1, ITS-2, and 28S rRNA regions. Both assays identified D. asiatica as the cause of infection, and no other filarial worm was detected.
This is the sort of case in which species-level identification changes the interpretation of the entire episode. Microscopy alone can tell a program that filarial larvae are present. It cannot reliably tell whether the infection is caused by an anthroponotic species targeted by elimination campaigns or by a zoonotic species maintained in animal reservoirs.
Trisomy 21 may have shaped the infection course
The report raises a biologically plausible explanation for persistent patent infection: the child’s underlying trisomy 21. Trisomy 21 is associated with impairment of both innate and adaptive immunity, and that immune vulnerability may have supported reproductive maturation of D. asiatica in this young host.
In a typical zoonotic encounter, humans are considered dead-end hosts for Dirofilaria species, and microfilaremia is rarely seen. Here, the parasite did not behave like an aborted incidental infection. It circulated in blood long enough to be detected repeatedly over >1 year, a pattern that suggests a permissive host environment or an unusually durable parasite-host relationship.
The case also illustrates how difficult it can be to separate true therapeutic failure from the practical limits of follow-up in community surveillance. The family was unreachable for a long stretch, imaging to search for adult worms could not be performed, and no direct examination of a tissue nodule or worm burden was possible.
Zoonotic filariasis can evade standard surveillance tools
Sri Lanka has now documented an expanding burden of human infection with zoonotic filarial worms. D. asiatica, formerly referred to as the Dirofilaria Hong Kong genotype, primarily infects dogs but can spill over into humans. Infected dogs are often subclinical, which makes reservoir control harder and quietly sustains exposure risk across communities.
The public health consequence is straightforward. Microscopy-based surveillance may miss species identity, and field-level morphology can misclassify zoonotic microfilariae as other filarial pathogens. In settings where elimination programs focus on human transmission alone, that creates a blind spot.
This case also sits beside earlier postvalidation surveillance in Sri Lanka, where Brugia-like microfilaremia was detected in 52 persons and molecular work identified Brugia Sri Lanka genotype without coinfections. The broader lesson is not about a single child. It is about a filarial ecosystem in which cryptic, zoonotic, and reservoir-associated species may circulate together.
Repeated diethylcarbamazine did not solve the problem on its own
Persistent microfilaremia after two courses of diethylcarbamazine suggests that current treatment assumptions may not translate cleanly to D. asiatica. The final clearance followed a regimen that combined a higher-dose diethylcarbamazine course with albendazole, but the report does not establish which component drove the response, whether delayed natural clearance played a role, or whether the organism had simply been suppressed below microscopic detection until later.
No established treatment protocol exists for human dirofilariasis with microfilaremia. Reported approaches, including ivermectin and anti-Wolbachia therapy with doxycycline, rely largely on experience with D. repens rather than controlled studies in D. asiatica. Very young children present another problem: ivermectin use is limited because safety and effectiveness have not been established in children weighing less than 15 kg.
In practice, that leaves clinicians with a narrow and imperfect toolkit. Repeated empiric therapy without species confirmation risks under-treating a zoonotic parasite while also obscuring the true epidemiology of infection.
Why this case changes the surveillance conversation
The most important feature of the report is not just persistence, but proof that D. asiatica can produce patent infection in a human child. That means blood-stage infection is possible, not merely tissue-localized disease with incidental microfilarial detection. For surveillance teams, species-discriminating molecular platforms become essential rather than optional.
The case also suggests that elimination programs focused solely on human reservoirs may leave zoonotic filarial transmission untouched. In Sri Lanka, canine prevalence of D. asiatica has been reported at about 33% in the southern and western regions, and molecular detections in dogs have increased across Asia. If animals sustain transmission, mass drug administration for humans cannot be expected to erase the underlying cycle.
The clinical record ends with a negative smear after the third treatment course, but the unanswered questions remain concrete: how often does D. asiatica produce persistent microfilaremia in humans, which hosts are at highest risk, and which regimen offers dependable clearance. Until those questions are answered, zoonotic filariasis will keep slipping through programs designed for a different parasite ecology.